Prognostic role of serum prostatic acid phosphatase for 103Pd-based radiation for prostatic carcinoma

International Journal of Radiation Oncology Biology Physics

Volumn 45, Issue 4, 1999, Pages 853-856

  Dattoli, Michael ^a   Wallner, Kent ^b   True, Lawrence ^c   Sorace, Richard ^a   Koval, John ^a   Cash, Jennifer ^a   Acosta, Rudolph ^a   Biswas, Mohendra ^a   Binder, Michael ^a   Sullivan, Brent ^a   Lastarria, Emilio ^a   Kirwan, Novelle ^a   Stein, Douglas ^a  

^a University Community Hospital Tampa   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Brachytherapy; Prostatic acid phosphatase; Prostatic carcinoma

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL TRIAL; ENZYME ACTIVITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA;

EID: 0032725114     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(99)00259-X     Document Type: Article

References (16)

1. Zagars G.K., Pollack A., Kavadi V.S. Prostate-specific antigen and radiation therapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 32:1995;293-306.
2. Partin A.W., Pound C.R., Clemens J.Q., et al. Serum PSA after anatomic radical prostatectomy The Johns Hopkins experience after 10 years . Urol Clin North Am. 20:1993;713-725.
3. Wallner K.E., Roy J., Harrison L. Tumor control and morbidity following transperineal I-125 implantation for Stage T1/T2 prostatic carcinoma. J Clin Oncol. 14:1996;449-453.
4. Whitesel J.A., Donohue R.E., Mani J.H., et al. Acid phosphatase Its influence on the management of carcinoma of the prostate . J Urol. 131:1984;70-72.
5. Bahnson R.R., Catalona W.J. Adverse implications of acid phosphatase levels in the upper range of normal. J Urol. 137:1987;427-430.
6. Lowe F.C., Trauzzi S.J. Prostatic acid phosphatase in 1993 Its limited clinical utility . Urol Clin North Am. 20:1993;589-595.
7. Dattoli M., Wallner K., Sorace R. Pd-103 brachytherapy and external beam irradiation for clinically localized, high-risk prostatic carcinoma. Int J Radiat Oncol Biol Phys. 35:1996;875-879.
8. Roy A.V., Brower M.E., Hayden J.E. Sodium thymolphthalein monophosphate A new acid phosphatase substrate with greater specificity for the prostatic enzyme in serum . Clin Chem. 17:1998;1093-1102.
9. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;457-481.
10. Salo J.O., Rannikko S. The value of acid phosphatase measurements in predicting extracapsular cancer growth before radical prostatectomy. Br J Urol. 62:1988;439-442.
11. Partin A.W., Carter H.B., Chan D.W., et al. Prostate specific antigen in the staging of localized prostate cancer Influence of tumor differentiation, tumor volume and benign hyperplasia . J Urol. 143:1990;747-752.
12. Stamey T.A., Kabalin J.N., McNeal J.E., et al. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. J Urol. 141:1989;1076-1083.
13. Lange P.H., Ercole C.J., Lightner D.J. The value of serum prostate specific antigen determinations before and after radical prostatectomy. J Urol. 141:1989;873-879.
14. Moul J.W., Connelly R.R., Perahia B., et al. The contemporary value of pretreatment prostatic acid phosphatase to predict pathological stage and recurrence in radical prostatectomy cases. J Urol. 159:1998;935-940.
15. Roach M., Pilepich M.V., Asbell S.O., et al. Long-term survival after radiotherapy alone Radiation Therapy Oncology Group prostate cancer trials . J Urol. 161:1999;864-868.
16. Guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys. 37:1997;1035-1041.